Daniel de Boer
Chief Executive Officer at PROQR THERAPEUTICS N.V.
Net worth: 2 M $ as of 2024-03-30
Profile
Daniel Anton de Boer is the founder of ProQR Therapeutics NV, PC Basic B.V., and Running It.
He held the position of Chief Executive Officer at each of these companies.
Additionally, he is also the founder of Amylon Therapeutics BV.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PROQR THERAPEUTICS N.V.
0.87% | 2023-12-30 | 705,309 ( 0.87% ) | 2 M $ | 2024-03-30 |
Daniel de Boer active positions
| Companies | Position | Start |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Chief Executive Officer | 2012-02-20 |
Former positions of Daniel de Boer
| Companies | Position | End |
|---|---|---|
| Running It | Chief Executive Officer | 2011-08-31 |
| PC Basic B.V. | Chief Executive Officer | 2008-01-31 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| Private companies | 3 |
|---|---|
| PC Basic B.V. | |
| Running It | |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Daniel de Boer
